Stay updated with breaking news from Ubmit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical trial of GT-02287 to... | May 12, 2023
Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third Quarter of 2023 CORAL GABLES, Fla., May 09, 2023 -- Catalyst... | May 9, 2023
We invite you to 2023 Itaú Day In this 100% digital meeting, investors and analysts may submit their questions to the executives, who will clarify their doubts and... | May 9, 2023
Announced positive topline data from the Phase 3 EMERGENT-3 trial of KarXT in schizophrenia in the first quarter of 2023 On track to submit New Drug Application for KarXT in schizophrenia with the... | May 4, 2023
Hereby we submit the audited annual information for the year 2022 approved by the ordinary General Meeting of Shareholders of Rokiskio suris, AB. Dalius Trumpa CEO Tel.:+370 458 55200 ... | April 28, 2023